From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Wearing a mask when in a public setting, staying a safe distance away from other people, and following CDC recommendations relative disinfecting and personal hygiene can help slow the spread of COVID-19. This is key to improving health and to our economic recovery. Joan Koerber-Walker, president & CEO, AZBio #MaskUpAZ #MaskUpArizona
C-Path’s Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint
Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplant recipients. TUCSON, Ariz., June 17, 2020 — Critical Path Institute (C-Path) announced today that its Transplant Therapeutics Consortium (TTC) has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the decision to […]
Banner Health and University of Arizona support national data collection effort to shed light on pandemic’s spread and impact
Amish Shah, MD is an emergency physician at Dignity Health and a member of the Arizona House of Representative elected by the people of LD24 – Central Phoenix and South Scottsdale. On Sunday, June 14, 2020, Dr. Shah shared the message below via Facebook. With his permission, we are sharing it with you.
- AZBioPEERS: What is my company worth? Establishing a valuation
- Preparing Your NIH SBIR/STTR CRP and Phase IIB Application
- Reducing Costs with BIO Business Solutions®
- AZBioPEERS: Perfecting your “virtual” pitch
- Arizona Bioscience Week - AZBW 2020
- 09/13/2020 - 09/19/2020